title: A Significant Statistical Advancement on the Predictive Values of ERCC1 Polymorphisms for Clinical Outcomes of Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: An Updated Meta-Analysis.
abstract: BACKGROUND
  There is no definitive conclusion so far on the predictive values of ERCC1 polymorphisms for clinical outcomes of platinum-based chemotherapy in non-small cell lung cancer (NSCLC). We updated this meta-analysis with an expectation to obtain some statistical advancement on this issue.
  
  
  METHODS
  Relevant studies were identified by searching MEDLINE, EMBASE databases from inception to April 2015. Primary outcomes included objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). All analyses were performed using the Review Manager version 5.3 and the Stata version 12.0.
  
  
  RESULTS
  A total of 33 studies including 5373 patients were identified. ERCC1 C118T and C8092A could predict both ORR and OS for platinum-based chemotherapy in Asian NSCLC patients (CT + TT versus CC, ORR: OR = 0.80, 95% CI = 0.67-0.94; OS: HR = 1.24, 95% CI = 1.01-1.53) (CA + AA versus CC, ORR: OR = 0.76, 95% CI = 0.60-0.96; OS: HR = 1.37, 95% CI = 1.06-1.75).
  
  
  CONCLUSIONS
  Current evidence strongly indicated the prospect of ERCC1 C118T and C8092A as predictive biomarkers for platinum-based chemotherapy in Asian NSCLC patients. However, the results should be interpreted with caution and large prospective studies are still required to further investigate these findings.
authors.affiliation: Department of Oncology, Jinan Central Hospital, Shandong University, Jinan, Shandong 250013, China; School of Medicine, Shandong University, Jinan, Shandong 250012, China.
authors.forename: Yali
authors.initials: Y
authors.lastname: Han
authors.affiliation: Department of Oncology, Jinan Central Hospital, Shandong University, Jinan, Shandong 250013, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Liu
authors.affiliation: Department of Oncology, Jinan Central Hospital, Shandong University, Jinan, Shandong 250013, China.
authors.forename: Meili
authors.initials: M
authors.lastname: Sun
authors.affiliation: School of Medicine, Shandong University, Jinan, Shandong 250012, China.
authors.forename: Zongpu
authors.initials: Z
authors.lastname: Zhang
authors.affiliation: Department of Oncology, Jinan Central Hospital, Shandong University, Jinan, Shandong 250013, China.
authors.forename: Chuanyong
authors.initials: C
authors.lastname: Liu
authors.affiliation: Department of Oncology, Jinan Central Hospital, Shandong University, Jinan, Shandong 250013, China.
authors.forename: Yuping
authors.initials: Y
authors.lastname: Sun
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D044466:Asian People / Q000235:genetics; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D004268:DNA-Binding Proteins / Q000235:genetics*; D004720:Endonucleases / Q000235:genetics*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000627:therapeutic use*; D020641:Polymorphism, Single Nucleotide; D011237:Predictive Value of Tests; D011446:Prospective Studies; D016019:Survival Analysis
chemical_list: D004268:DNA-Binding Proteins; D009944:Organoplatinum Compounds; C071447:ERCC1 protein, human; D004720:Endonucleases